VYVANSE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vyvanse, and when can generic versions of Vyvanse launch?
Vyvanse is a drug marketed by Takeda Pharms Usa and is included in two NDAs.
The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. Fifteen suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vyvanse
A generic version of VYVANSE was approved as lisdexamfetamine dimesylate by ALKEM LABS LTD on August 25th, 2023.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VYVANSE?
- What are the global sales for VYVANSE?
- What is Average Wholesale Price for VYVANSE?
Summary for VYVANSE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 23 |
Clinical Trials: | 65 |
Patent Applications: | 150 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VYVANSE |
Drug Sales Revenues: | Drug sales revenues for VYVANSE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VYVANSE |
What excipients (inactive ingredients) are in VYVANSE? | VYVANSE excipients list |
DailyMed Link: | VYVANSE at DailyMed |
![VYVANSE drug patent expirations Drug patent expirations by year for VYVANSE](/p/graph/s/t/VYVANSE-patent-expirations.png)
![Drug Prices for VYVANSE](/p/graph/drug-price/VYVANSE.png)
![Drug Sales Revenue Trends for VYVANSE](/p/graph/drug-sales-revenues/VYVANSE.png)
Recent Clinical Trials for VYVANSE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Minnesota | Early Phase 1 |
Yale University | Phase 2/Phase 3 |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2/Phase 3 |
Pharmacology for VYVANSE
Drug Class | Central Nervous System Stimulant |
Physiological Effect | Central Nervous System Stimulation |
Paragraph IV (Patent) Challenges for VYVANSE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VYVANSE | Capsules | lisdexamfetamine dimesylate | 10 mg | 021977 | 1 | 2020-04-09 |
VYVANSE | Capsules | lisdexamfetamine dimesylate | 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg | 021977 | 6 | 2011-02-23 |
US Patents and Regulatory Information for VYVANSE
International Patents for VYVANSE
See the table below for patents covering VYVANSE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2740256 | NOUVEAUX COMPOSES PHARMACEUTIQUES A LIBERATION PROLONGEE DESTINES A EMPECHER LA CONSOMMATION ABUSIVE DE SUBSTANCES CONTROLEES (NOVEL SUSTAINED RELEASE PHARMACEUTICAL COMPOUNDS TO PREVENT ABUSE OF CONTROLLED SUBSTANCES) | ⤷ Sign Up |
Austria | 462412 | ⤷ Sign Up | |
South Korea | 20040088519 | ⤷ Sign Up | |
Australia | 8659901 | Active agent delivery systems and methods for protecting and administering active agents | ⤷ Sign Up |
Japan | 2002540073 | ⤷ Sign Up | |
European Patent Office | 1257592 | UTILISATION DE LA CONFORMATION D'UNE PROTEINE POUR LA PROTECTION ET LA LIBERATION DE COMPOSES CHIMIQUES (USE OF PROTEIN CONFORMATION FOR THE PROTECTION AND RELEASE OF CHEMICAL COMPOUNDS) | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 03072047 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VYVANSE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1644019 | 1390058-4 | Sweden | ⤷ Sign Up | PRODUCT NAME: LISDEXAMFETAMIN VALFRITT I FORMEN AV ETT FARMACEUTISKT GODTAGBART SALT, SAERSKILT ETT MESYLATSALT; NAT. REG. NO/DATE: 47382 20130722; FIRST REG.: GB PL 08081/0050-52 20130201 |
1644019 | LUC00189 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: LISDEXAMFETAMINE, OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; AUTHORISATION NUMBER AND DATE: PL08081/0050-52 20200901 |
1644019 | CR 2013 00043 | Denmark | ⤷ Sign Up | PRODUCT NAME: LISDEXAMFETAMIN, EVENTUELT I FORM AF ET MESYLAT ELLER HYDROCHLORID SALT DERAF; NAT. REG. NO/DATE: MT499080, MT499081, MT499082 20130214; FIRST REG. NO/DATE: PL PL 08081/0050-0052 20130201 |
1644019 | 37/2016 | Austria | ⤷ Sign Up | PRODUCT NAME: LISDEXAMFETAMIN, OPTIONAL IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON, INSBESONDERE EINES MESILAT-SALZES; NAT. REGISTRATION NO/DATE: 136851-136853 20160412; FIRST REGISTRATION: PL08081/0050-PL08081/0052 20130201 |
1644019 | C01644019/01 | Switzerland | ⤷ Sign Up | VERTRETERLOESCHUNG |
1644019 | CA 2013 00043 | Denmark | ⤷ Sign Up | PRODUCT NAME: LISDEXAMFETAMIN, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER ET MESYLAT SALT; NAT. REG. NO/DATE: MT499080, MT499081, MT499082 20130214; FIRST REG. NO/DATE: PL PL 08081/0050-0052 20130201 |
1644019 | 301019 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LISDEXAMFETAMINE, DESGEWENST IN DE VORM VAN EEN MESYLAAT- OF HYDROCHLORIDEZOUT DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 124498 20190528; FIRST REGISTRATION: GB PL 08081/0050-52 20130201 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |